So why haven't we investors seen the Phase K data?
Post# of 72436
![](/assets/46931549/no_avatar_available_thumb.jpg)
The FDA was presented it. Sure would help the SP.
"Cellceutix executives met this week with staff of the FDA Division of Oncology Products 1 to discuss the Kevetrin Phase 1 study data, as well as a proposed design of a planned Phase 2 trial in patients with ovarian cancer that have resistance to platinum-based therapy.
The FDA has agreed with Cellceutix's plan to initiate such a trial, and based upon the data from the Phase 1 trial, that the administration of Kevetrin doses at three times per week would be acceptable."
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)